EssilorLuxottica Acquires Signifeye, Expanding Ophthalmology Clinics Footprint
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 2 hour ago0mins
- Acquisition Expansion: EssilorLuxottica announced the acquisition of Signifeye, a leading Belgian ophthalmology platform with 15 eye centers in the Flanders region, further enhancing its ophthalmology network in Europe.
- Integration Advantage: This transaction follows the recent acquisition of Optegra, which operates over 70 clinics across the UK, Czech Republic, Poland, Slovakia, and the Netherlands, strengthening EssilorLuxottica's market position in Europe.
- Medical Innovation: By integrating Signifeye's clinical excellence with EssilorLuxottica's medical and scientific innovation capabilities, the company can provide a full spectrum of eye healthcare services, enhancing the patient experience from prevention to specialized clinical management.
- Future Outlook: The transaction is expected to close by Q1 2026, marking a transformative collaboration that will drive the future of eye care alongside EssilorLuxottica and Optegra.
EL.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on EL
Wall Street analysts forecast EL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EL is 104.06 USD with a low forecast of 70.00 USD and a high forecast of 122.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
7 Buy
8 Hold
1 Sell
Moderate Buy
Current: 107.280
Low
70.00
Averages
104.06
High
122.00
Current: 107.280
Low
70.00
Averages
104.06
High
122.00
Goldman Sachs
Buy
maintain
2025-12-05
Reason
Goldman Sachs
Price Target
2025-12-05
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on EssilorLuxottica to EUR 350 from EUR 315 and keeps a Buy rating on the shares. The firm's increased price target is driven by higher organic growth led by Wearables momentum as well as revised discounted cash flow assumptions, the analyst tells investors
Rothschild & Co Redburn
Chris Pitcher
Neutral -> Sell
downgrade
$83 -> $70
2025-11-25
Reason
Rothschild & Co Redburn
Chris Pitcher
Price Target
$83 -> $70
2025-11-25
downgrade
Neutral -> Sell
Reason
Rothschild & Co Redburn analyst Chris Pitcher downgraded Estee Lauder to Sell from Neutral with a price target of $70, down from $83. The company is early in its transformation and the shares have rally on the hopes of a strong turnaround, the analyst tells investors in a research note. However, the firm believes that despite improving sales growth, Estee needs deeper investment, which puts its scale of the margin recovery at risk.
Rothschild & Co Redburn
Neutral -> Sell
downgrade
$83 -> $70
2025-11-25
Reason
Rothschild & Co Redburn
Price Target
$83 -> $70
2025-11-25
downgrade
Neutral -> Sell
Reason
Rothschild & Co Redburn downgraded Estee Lauder to Sell from Neutral with a price target of $70, down from $83. The company is early in its transformation and the shares have rally on the hopes of a strong turnaround, the analyst tells investors in a research note. However, the firm believes that despite improving sales growth, Estee needs deeper investment, which puts its scale of the margin recovery at risk.
Argus
Hold
to
Buy
upgrade
2025-11-11
Reason
Argus
Price Target
2025-11-11
upgrade
Hold
to
Buy
Reason
Argus upgraded Estee Lauder to Buy from Hold.
See All Ratings
About EL
The Estee Lauder Companies Inc. is a manufacturer, marketer and seller of skin care, makeup, fragrance and hair care products. Its product categories include skin care, makeup, fragrance, hair care and others. Its products are sold in approximately 150 countries and territories under a number of brand names, including Estee Lauder, Aramis, Clinique, Lab Series, Origins, M.A.C, Bobbi Brown Cosmetics, La Mer, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frederic Malle, GLAMGLOW, Kilian Paris, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD. It is a licensee for fragrances, cosmetics and/or related products for AERIN, BALMAIN, and Dr. Andrew Weil. Its skin care products include moisturizers, serums, cleansers, toners, exfoliators, facial masks, body care, sun care products and others. Its makeup products include lipsticks, lip glosses, mascaras, foundations and others.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How does the AI Scent Advisor replicate in-store fragrance consultations online?
What are the key features of the AI Scent Advisor launched by Estée Lauder?
How will Estée Lauder's restructuring efforts impact its financial performance by FY27?
What is the likely future impact of China's economic slowdown on Estée Lauder?